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OBJECTIVES The purpose of this study was to determine quality of life (QOL) and exercise performance
(EP) in patients with persistent atrial fibrillation (AF) converted to sinus rhythm (SR)
compared with those remaining in or reverting to AF.
BACKGROUND Restoration of SR in patients with AF improving QOL and EP remains controversial.
METHODS Patients with persistent AF were randomized double-blind to amiodarone, sotalol, or placebo.
Those not achieving SR at day 28 were cardioverted and classified into SR or AF groups at
8 weeks (n  624) and 1 year (n  556). The QOL (SF-36), symptom checklist (SCL),
specific activity scale (SAS), AF severity scale (AFSS), and EP were assessed.
RESULTS Favorable changes were seen in SR patients at 8 weeks in physical functioning (p  0.001),
physical role limitations (p  0.03), general health (p  0.002), and vitality (p  0.001), and
at 1 year in general health (p  0.007) and social functioning (p  0.02). Changes in the
scores for SCL severity (p  0.01), functional capacity (p  0.003), and AFSS symptom
burden (p  0.001) at 8 weeks and in SCL severity (p  0.01) and AF symptom burden
(p  0.001) at 1 year showed significant improvements in SR versus AF. Symptomatic
patients were more likely to have improvement. The EP in SR versus AF was greater from
baseline to 8 weeks (p  0.01) and to 1 year (p  0.02). The EP correlated with physical
functioning and functional capacity except in the AF group at 1 year.
CONCLUSIONS In patients with persistent AF, restoration and maintenance of SR was associated with
improvements in QOL measures and EP. There was a strong correlation between QOL
measures and EP. (J Am Coll Cardiol 2006;48:721–30) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.051of Cardiology Foundation
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rtrial fibrillation (AF) is the most common cardiac arrhyth-
ia, affecting over 2 million Americans, and is the most
requent cause for hospitalization among disorders of car-
iac rhythm (1). Atrial fibrillation is associated with an
ncreased risk of stroke related to thromboembolism, which
an be reduced with anticoagulation (2). Atrial fibrillation
ay also lead to tachycardia-induced cardiomyopathy with
ymptoms and signs of heart failure (3).
See page 731
In the wake of recent neutral mortality impact of resto-
ation and maintenance of sinus rhythm (SR), there has
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ffice of Research and Development (Washington, DC), Berlex Laboratories, and
yeth-Ayerst Laboratories.p
Manuscript received October 13, 2005; revised manuscript received February 28,
006, accepted March 7, 2006.een an increasing focus on the control of ventricular rate
ombined with anticoagulation as an initial treatment ap-
roach to AF (4). On the other hand, patients remaining in
F often continue to experience disabling symptoms and
oor exercise tolerance that may significantly compromise
heir quality of life (QOL) (5). Researchers and clinicians
ontinue to recognize the importance of the patient’s
erspective in the assessment of health care treatments (6).
hus, QOL is becoming an important focus for the assess-
ent of treatments for AF (7–9).
The present QOL evaluation is a substudy of the
AFE-T (Sotalol Amiodarone Atrial Fibrillation Efficacy
rial) study (10) to test the hypothesis that restoration and
aintenance of SR in patients with persistent AF improves
OL and exercise performance (EP).
ETHODS
tudy design. The details of the study (SAFE-T) design
rom which the data are derived have been reported previ-
usly (11). In brief, patients with persistent AF were
andomly assigned double-blind to amiodarone, sotalol, or
lacebo after optimal anticoagulation (international normal-
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QOL With Sinus Rhythm or AF August 15, 2006:721–30zed ratio 2 to 3). After 4 weeks of therapy, those not in SR
ad their AF electrically cardioverted. Once SR was
chieved, anticoagulation was continued for at least 8 weeks
hereafter. Recurrence of AF was documented by weekly
ranstelephonic monitoring. All patients were followed for
t least 1 year. Patients remaining in SR were maintained on
heir originally assigned treatment. Those who remained in
r reverted to AF after a second cardioversion were placed
n open-label medications with continued follow-up to 1
ear. During AF the objective was to slow the ventricular
ate to 60 to 90 beats/min, which was achieved by using
iltiazem, verapamil, and/or digoxin. For the present sub-
tudy, patients were classified into the SR group or the AF
roup according to their rhythm status at follow-up visits.
OL measurements and exercise treadmill test. General
ealth-related QOL was evaluated using the Medical Out-
omes Study Short Form-36 (SF-36) questionnaire. It
ontains 8 subscales: physical functioning, physical role
imitations, bodily pain, general health, vitality, social func-
ioning, emotional role limitations, and mental health.
cores range from 0 to 100, with lower scores representing
poorer QOL. Disease-specific measures of QOL included
he arrhythmia-related Symptom Checklist (SCL), which
ontains 16 questions and assesses both symptom frequency
nd severity with scores ranging from 0 to 64 for the former
nd 0 to 48 for the latter (12). The higher scores indicate
ore frequent and serious symptoms. The Specific Activity
cale (SAS) measures subjective functional capacity and
onsists of 20 items (13). The score of this scale ranges from
to 80 with a higher score representing more difficulty in
arrying on physical activities. The Atrial Fibrillation Se-
erity Scale (AFSS), a 12-item AF-specific scale, was
ncluded to evaluate subjective rating of AF symptom
urden (14). The AF symptom burden score derived from
FSS is a summary score which averages the frequency,
uration, and severity of AF episodes; a higher score
ndicates a greater AF symptomatology. The modified
aughton protocol was used for performing exercise tread-
ill tests as described previously (10,11). The QOL evalu-
tion and exercise treadmill tests were performed at baseline
nd at the 8 weeks and 1 year follow-up visits.
tatistical analysis. The present substudy focused on 2
Abbreviations and Acronyms
AF  atrial fibrillation
AFSS  atrial fibrillation severity scale
BMI  body mass index
EP  exercise performance
LAD  left atrial dimension
LVEF  left ventricular ejection fraction
QOL  quality of life
SAS  specific activity scale
SCL  symptom checklist
SR  sinus rhythmroups of patients: 624 patients who completed 8 weeks of mollow-up (4 weeks after cardioversion) and 557 patients
ho completed 1 year of follow-up. To evaluate the effect of
hythm on QOL and EP, the patients were classified into
he SR group or AF group according to their rhythm status
t 8 weeks or 1 year, regardless of the intermittent rhythm
hanges during the follow-up. The SR group included
atients who converted to and remained in sinus rhythm;
he AF group included patients who remained in or reverted
o AF. The differences between the SR and AF groups in
hange of QOL scores and EP during treadmill testing from
aseline to 8 weeks and from baseline to 1 year were
ompared using the 2-sample t test. The differences in such
hanges were also assessed using analysis of covariance
ontrolling for baseline characteristics including age, body
ass index (BMI), duration of AF, left ventricular ejection
raction (LVEF), left atrial dimension (LAD), presence of
ypertension, study drug assignment, and success of cardio-
ersion. Within-group changes were analyzed by the paired
test.
To determine whether maintaining SR exerted a greater
ffect on QOL and EP in patients with AF symptoms
defined as palpitations, syncope, lightheadedness, shortness
f breath, chest pain, or fatigue) than in those without
ymptoms, we compared the changes from the baseline to 8
eeks and from baseline to 1 year between the SR and AF
roups based on whether patients experienced these AF
ymptoms at baseline. The same statistical tests were per-
ormed for these analyses: The 2-sample t test was used to
est differences in change between the AF and SR groups,
nd the paired t test was used to test within-group changes.
he degree of association between QOL measures and
linical measures was calculated by Pearson correlation
oefficient. All p values reported were based on 2-sided
ests; p  0.05 was the criterion for statistical significance.
nalyses were performed with the use of SAS software,
ersion 8 (SAS Institute, Cary, North Carolina).
Effect size, defined as the difference between groups in
he mean changes from baseline divided by the pooled
tandard deviation of the changes, was calculated to assess
he clinical importance of differences in the general QOL
easures (15). An effect size exceeding 0.2 was considered
linically meaningful (16–19).
ESULTS
atient characteristics. The baseline characteristics of pa-
ients in SR and those in AF are presented in Table 1. Six
undred twenty-four patients were followed to 8 weeks, in
hich 305 were in the SR group and 319 in the AF group.
mong the 557 patients who completed 1 year of follow-up,
47 were in the SR group and 210 were in the AF group.
verall, the mean age was 67 years and 99% were male.
atients in SR and in AF had a mean BMI of 30.5 kg/m2
nd 32.4 kg/m2, respectively. The respective figures for the
ean LAD in patients in SR and in AF were 47.0 and 49.1
m (p  0.001). A larger number of patients in the SR
g
w
a
6
T
w
Q
8
8
c
p
w
f
g
w
s
p
m
b
T
s
s
t
r
0
d
S
o
b
t
s
A
0
8
f
r
Q
s
S
g
a
m
l
(
p
c
s
i
(
t
C
v
s
F
a
g
f
p
b
t
d
b
s
S
g
s
723JACC Vol. 48, No. 4, 2006 Singh et al.
August 15, 2006:721–30 QOL With Sinus Rhythm or AFroup were on the randomly assigned study drugs compared
ith those in the AF group (p  0.001). On average,
pproximately 63% of patients experienced AF symptoms,
6% had hypertension, and 25% had ischemic heart disease.
he clinical characteristics of patients followed for 1 year
ere similar to those followed for 8 weeks.
uality of life. The QOL measurements were available for
9% of the patients (554 of 624) followed to 8 weeks and
9% (496 of 557) of those followed to 1 year. The mean
hanges in QOL scores from baseline to 8 weeks between
atients in SR and those in AF are shown in Table 2. At 8
eeks, there were significant improvements in physical
unctioning (p 0.001), physical role limitation (p 0.03),
eneral health (p  0.002), and vitality (p  0.001); there
ere also significant improvements in patients with SR in
ymptom severity (p  0.01), functional capacity (SAS;
 0.003), and AF symptom burden (p  0.001). The
ean changes in QOL scores from baseline to 1 year
etween patients in SR and those in AF are shown in
able 3. In those followed for 1 year, SR patients had
ignificant improvements in general health (p  0.007) and
ocial functioning (p  0.02) compared with the AF pa-
ients. Symptom frequency and severity was significantly
educed in the SR group compared with the AF group (p 
.05 and p  0.001, respectively), and AF symptom burden
ecreased remarkably among the patients who maintained
R versus those who were in AF (p  0.001). These
utcomes did not change after adjustments were made for
aseline age, BMI, LAD, AF duration, presence of hyper-
ension, the assignment of the randomized treatment, and
uccess of cardioversion. The effect sizes comparing SR to
F on physical functioning, general health, and vitality were
.32, 0.26, and 0.28 standard deviation units, respectively, at
Table 1. Patient Characteristics at Baseline AF
Age (yrs)
Male (% of patients)
Treatment assignment (% of patients)
Amiodarone
Sotalol
Placebo
Body mass index (kg/m2)
Duration of AF before treatment (% of patients)
1 yr
1 yr
Perceived symptomatic AF (% of patients)
Hypertension (% of patients)
Ischemic heart disease (% of patients)
Ventricular rate (beats/min)
Ejection fraction (%)
Left atrial dimension (mm)
Use of rate control medications
Digoxin (% of patients)
Calcium channel blocker (% of patients)
Other (% of patients)
AF  atrial fibrillation; SR  sinus rhythm.weeks; the effect sizes for general health and social sunctioning were 0.27 and 0.23 standard deviation units,
espectively, at 1 year.
OL in symptomatic versus asymptomatic AF. Figure 1
hows comparisons of the mean changes in QOL scores for
R versus AF within symptomatic and asymptomatic sub-
roups for patients followed to 8 weeks. For the symptom-
tic subgroup, patients in SR reported a significant improve-
ent in physical functioning (p  0.02), physical role
imitation (p  0.03), general health (p  0.007), vitality
p  0.003), symptom severity (p  0.003), functional ca-
acity (p  0.03), and AF symptom burden (p  0.001)
ompared with patients in AF. For the asymptomatic
ubgroup, improvement in QOL measures among patients
n SR included physical functioning (p  0.004), vitality
p  0.05), functional capacity (p  0.02), and AF symp-
om burden (p  0.001) compared with patients in AF.
omparisons of the mean changes in QOL scores for SR
ersus those for AF within symptomatic or asymptomatic
ubgroups for patients followed to 1 year are shown in
igure 2. The SR patients in the symptomatic subgroup had
greater improvement in physical functioning (p  0.05),
eneral health (p  0.004), vitality (p  0.05), and social
unctioning (p  0.03), compared with their AF counter-
arts. It was noted that symptom severity and AF symptom
urden decreased significantly in SR patients in the symp-
omatic subgroup (p  0.001). In contrast, there were no
ifferences in improvement in all QOL measures but 1
etween SR patients and AF patients in the asymptomatic
ubgroup at 1 year.
For the symptomatic patients, the effect sizes comparing
R to AF on physical functioning, physical role limitation,
eneral health, and vitality were 0.27, 0.24, 0.31, and 0.33
tandard deviation units, respectively, at 8 weeks; the effect
SR Group
(n  305)
AF Group
(n  319) p Values
67.3  9.0 66.4  9.5 0.19
99.0 99.7 0.29
48.5 33.5 0.001
42.3 34.5
9.2 32.0
30.5  5.6 32.4  6.0 0.001
86.6 73.4 0.001
13.4 26.6
59.0 65.2 0.11
67.3 65.2 0.58
25.3 24.1 0.75
81.0  14.3 82.1  15.6 0.37
40.1  12.3 51.1  12.1 0.30
47.0  6.7 49.1  7.0 0.001
45.9 50.5 0.25
57.1 58.9 0.63
0.7 0.3 0.54izes for physical functioning, general health, vitality, and
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QOL With Sinus Rhythm or AF August 15, 2006:721–30ocial functioning were 0.23, 0.36, 0.24, and 0.26, respec-
ively, at 1 year. For the asymptomatic patients, the effect
izes for physical function and vitality were 0.41 and 0.27
tandard deviation units at 8 weeks.
xercise performance. The EP measurements were avail-
ble for 57% of the patients (358 of 624) followed to 8
eeks and 60% (332 of 557) of those followed to 1 year.
igure 3 shows the comparisons of the mean changes in
aximal exercise duration. Overall, the increase in exercise
olerance in the SR group was significantly higher than that
n the AF group at 8 weeks (81.5 s vs. 33.5 s; p  0.01) and
t 1 year (74.6 s vs. 15.2 s; p  0.02). The exercise duration
as not significantly affected by amiodarone or sotalol. For
he symptomatic subgroup, a greater increase in exercise
uration was observed in SR patients (n  123) versus AF
Table 2. Mean Change in Quality of Life Sco
Quality of Life Measure
SR Gr
(n  2
Mean 
SF-36 scales*§
Physical functioning
Baseline AF 60.1 
Change from baseline to 8 weeks 5.5 
Physical role limitations
Baseline AF 49.8 
Change from baseline to 8 weeks 8.0 
General health
Baseline AF 62.0 
Change from baseline to 8 weeks 3.5 
Vitality
Baseline AF 51.6 
Change from baseline to 8 weeks 6.1 
Bodily pain
Baseline AF 70.4 
Change from baseline to 8 weeks 0.1 
Social functioning
Baseline AF 77.3 
Change from baseline to 8 weeks 2.4 
Emotional role limitations
Baseline AF 63.6 
Change from baseline to 8 weeks 4.1 
Mental health
Baseline AF 75.5 
Change from baseline to 8 weeks 0.1 
Symptom checklist frequency
Baseline AF 16.6 
Change from baseline to 8 weeks 2.7 
Symptom checklist severity
Baseline AF 13.6 
Change from baseline to 8 weeks 1.8 
Specific activity scale¶
Baseline AF 20.3 
Change from baseline to 8 weeks 2.4 
AF symptom burden score#
Baseline AF 13.2 
Change from baseline to 8 weeks 6.5 
Within-group change: *p  0.05; †p  0.01; ‡p  0.001. §H
more frequent and serious symptom. ¶Higher score indicates
AF burden.
AF  atrial fibrillation; SF-36  Short Form-36; SR atients (n  102) at 8 weeks (80.1 s vs. 17.3 s; p  0.006); chere was a trend toward improvement in exercise perfor-
ance among SR patients (n  136) compared with AF
atients (n  69) at 1 year (72.2 s vs. 11.1 s; p  0.08).
owever, significant differences in improvement of exercise
olerance between SR and AF groups were not observed in
he asymptomatic subgroup at 8 weeks and 1 year. The
bserved differences between the SR and AF groups were
ot altered after the adjustment for a group of the baseline
atient characteristics.
orrelations between exercise performance and QOL
easures. Correlations between exercise duration and
OL measures were examined to determine the nature of
he association between objective measures and subjective
easures of physical function in patients who maintained
R versus those who remained in or reverted to AF. The
rom Baseline to 8 Weeks
AF Group
(n  271) SR vs. AF
Mean  SD Difference p Value
55.7  27.3
1.3  20.8 6.8 0.001
39.9  42.0
1.2  33.7 6.9 0.03
56.6  21.0
0.6  16.9 4.1 0.002
46.8  23.9
1.0  18.5 5.1 0.001
65.8  28.0
2.0  22.5 1.9 0.34
73.7  27.7
1.1  23.9 3.5 0.10
63.0  42.6
2.3  42.1 6.4 0.10
73.9  19.0
0.6  16.4 0.5 0.73
19.1  10.9
2.9  9.7‡ 0.13 0.86
15.6  9.0
0.4  6.4 1.4 0.01
24.4  18.9
1.3  13.8 3.7 0.003
13.5  6.8
0.2  6.7 6.8 0.001
score indicates better quality of life. Higher score indicates
ifficulty in physical activities. #Higher score indicates greater
rhythm.res F
oup
83)
SD
27.6
22.0‡
43.1
39.2‡
20.5
14.8‡
23.7
18.6‡
25.7
24.6
25.6
26.0
42.6
46.7
18.2
15.0
10.2
7.7‡
8.6
6.8‡
18.4
15.4†
7.0
7.3‡
igher
more dorrelation coefficients (r) for exercise duration and QOL
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August 15, 2006:721–30 QOL With Sinus Rhythm or AFeasures are presented in Table 4. Exercise duration at 8
eeks correlated systematically with 5 SF-36 subscales in
R patients and with 3 SF-36 subscales in AF patients. At
weeks, EP had stronger correlation with patient-perceived
hysical functioning in both the AF and the SR groups
r  0.28 and r  0.36, respectively). At 1 year, EP was
ssociated with all but 1 SF-36 subscale in patients remain-
ng in SR (r  0.19 to 0.47); however, none of the SF-36
ubscales correlated with exercise duration in patients re-
aining in AF. There was no correlation between EP and
he mental health subscale regardless of rhythm status and
ength of follow-up. Exercise capacity correlated well with
unctioning capacity, with the correlation coefficient ranging
rom 0.39 to 0.49 in all groups except the AF group at
Table 3. Mean Change in Quality of Life Sco
Quality of Life Measure
SR Grou
(n  320
Mean  S
SF-36 scales§
Physical functioning
Baseline AF 58.6  28
Change from baseline to 1 yr 2.1  23
Physical role limitations
Baseline AF 47.5  42
Change from baseline to 1 yr 4.1  40
General health
Baseline AF 59.8  21
Change from baseline to 1 yr 0.1  17
Vitality
Baseline AF 50.1  24
Change from baseline to 1 yr 3.6  20
Bodily pain
Baseline AF 68.9  26
Change from baseline to 1 yr 2.5  25
Social functioning
Baseline AF 75.8  26
Change from baseline to 1 yr 1.4  25
Emotional role limitations
Baseline AF 62.9  42
Change from baseline to 1 yr 0.5  49
Mental health
Baseline AF 75.3  19
Change from baseline to 1 yr 1.7  16
Symptom checklist frequency
Baseline AF 17.8  10
Change from baseline to 1 yr 4.5  8.8
Symptom checklist severity
Baseline AF 14.6  9.0
Change from baseline to 1 yr 3.2  7.3
Specific activity scale¶
Baseline AF 21.5  19
Change from baseline to 1 yr 0.4  16
AF symptom burden score#
Baseline AF 13.3  7.3
Change from baseline to 1 yr 7.6  7.9
Within-group change: *p  0.05; †p  0.01; ‡p  0.001. §H
more frequent and serious symptom. ¶Higher score indicates
AF burden.
Abbreviations as in Table 2.year. cssessment of missing data. Among patients followed to
weeks and those followed to 1 year, approximately 93% of
he patients in SR and 85% in AF completed QOL
uestionnaires at baseline and at follow-up visits. Seventy
ercent of the patients in SR and 46% in AF completed the
xercise tests at baseline and at 8 weeks, and 63% of patients
n SR and 54% in AF performed the exercise tests at
aseline and at the 1-year visit. To assess the effect of
issing data, the baseline values in patients who completed
he QOL questionnaires were compared with those in
atients who did not complete them. There was no statis-
ical difference in demographic and clinical measures. More-
ver, a similar comparison between patients who had the
xercise test at follow-up visits and those who did not
rom Baseline to 1 Year
AF Group
(n  176) SR vs. AF
Mean  SD Difference p Value
57.4  25.7
1.3  21.5 3.4 0.11
44.9  42.9
1.5  43.1 2.7 0.50
61.3  20.3
4.7  18.5‡ 4.6 0.007
49.0  22.3
0.8  19.5 2.8 0.14
68.6  28.5
2.7  28.0 0.14 0.95
78.2  25.6
4.2  24.6* 5.6 0.02
65.1  42.6
3.2  49.5 3.7 0.44
76.0  17.9
2.1  18.6 0.4 0.82
18.8  10.9
2.8  10.8‡ 1.7 0.05
14.5  8.5
0.5  6.5 2.7 0.001
22.5  16.6
1.7  13.1 1.3 0.37
13.5  6.6
0.5  7.6 7.1 0.001
score indicates better quality of life. Higher score indicates
ifficulty in physical activities. #Higher score indicates greaterres F
p
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QOL With Sinus Rhythm or AF August 15, 2006:721–30or the mean BMI, which was 10% higher in patients who
id not undergo the test compared with those who did
omplete it (p  0.01).
ISCUSSION
he data for the present substudy was derived from the
AFE-T study (10). The clinical correlates of sustained SR
ersus persistent AF relative to QOL, EP, and their
nteractions were defined. The results showed that restora-
ion and maintenance of SR were associated with significant
ncreases in a number of QOL measures as well as signifi-
ant improvements in EP. The data also indicated that
atients who were symptomatic at baseline were more likely
o have improvement in QOL compared with those who
ere asymptomatic. A novel finding of the substudy was the
trong correlation between exercise duration, an objective
easure, and QOL, a subjective measure, of physical
igure 1. Sinus rhythm (SR) versus atrial fibrillation (AF) comparisons on
F symptoms. *p  0.05; **p  0.01; ***p  0.001. (A) Symptomatic pati
roup: n  116; AF group: n  92). SCL  symptom checklist; SF-36unction in patients who maintained SR versus those who oersisted in or reverted to AF. Thus, our data have relevance
o the conversion and maintenance of SR in patients with
ersistent AF.
revious reports on QOL in AF Versus SR. Across most
OL domains of the SF-36, patients with persistent or
ntermittent AF consistently experience a greatly worse
OL compared with that of healthy controls (7–9,14,20).
owever, the clinical evidence that conversion and mainte-
ance of SR in patients with AF may predictably result in
mprovement of QOL continues to be the subject of
igorous debate (21,22). The debate may have stemmed
argely from the results of the AFFIRM trial (4). Most of
he patients in the AFFIRM trial had paroxysmal AF, and
either QOL nor EP based on the 6-minute walk test was
ound to be superior in patients with AF converted to SR
22). However, subsequent on-therapy analyses of the
FFIRM data in the setting of restoration and maintenance
changes in quality-of-life scores from baseline to 8 weeks by presence of
SR group: n  167; AF group: n  179). (B) Asymptomatic patients (SR
ort Form-36.mean
ents (f SR revealed a mortality benefit that was deemed to be
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August 15, 2006:721–30 QOL With Sinus Rhythm or AFffset by the adverse effects of antiarrhythmic drugs (23) in
he parent trial.
In the AFFIRM trial, 40% of the patients in the SR
trategy arm were actually in AF, which may have influ-
nced the trial outcomes. In contrast, in the PIAF (Phar-
acologic Intervention in Atrial Fibrillation) study (n 
52), there was no difference in QOL between the 2
reatment groups, but EP did increase in patients restored to
nd maintained in SR compared with those remaining in
F (24). Nevertheless, there have been a number of recent
linical trials (10,14,20) that have demonstrated significant
mprovements in QOL in patients with AF converted to SR.
he substudy of the RACE (Rate Control Versus Electrical
ardioversion) trial showed that, in patients with symptomatic
ersistent AF, restoration of SR increased QOL as measured
igure 2. Sinus rhythm (SR) versus atrial fibrillation (AF) comparisons o
y presence of AF symptoms. *p  0.05; **p  0.01; ***p  0.001. (A) Sym
atients (SR group: n  118; AF group: n  65). SCL  symptom checy SF-36 questionnaires (25). The CTAF (Canadian Trial of Ttrial Fibrillation), using the SF-36 and the same disease-
pecific instruments used in the present substudy in patients
ith symptomatic AF, found QOL improvements over time
hich were not significantly different across drug groups
amiodarone, sotalol, and propafenone) even though
miodarone was superior in maintaining normal SR (14).
OL during SR versus AF in varying study populations.
he improvement in QOL on restoration and maintenance
f SR is not confined solely to drug-induced maintenance of
R. Significant QOL enhancement also occurs when SR is
estored and maintained after catheter ablation (12,13,26)
r surgery, as in the case of mitral stenosis (27). Therefore,
ur data indicate that the critical issue here is conversion
nd maintenance of SR from AF rather than the method
hereby it is achieved in the pursuit of augmented QOL.
parison of mean changes in quality-of-life scores from baseline to 1 year
atic patients (SR group: n  202; AF group: n  111). (B) Asymptomatic
SF-36  Short Form-36.n com
ptomhe data from the substudy of the SAFE-T study have also
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QOL With Sinus Rhythm or AF August 15, 2006:721–30ndicated that patients with AF who had symptoms at
aseline were more likely to have improvements in QOL on
onversion to SR compared with those who were asymp-
omatic. At 8-week follow-up, patients who were in AF at
aseline and who were now in SR had significant improve-
ents in 7 QOL scores for the symptomatic subgroup and
n 4 QOL scores for the asymptomatic subgroup. The
recise basis for such a difference is unclear but may be
elated to the variability in the nature and severity of the
nderlying disease inducing the AF. Alternatively, it may
ossibly be due to the smaller population of subjects in the
tudy exhibiting the phenomenon of “silent” AF. It should
e emphasized that on active drug therapy 20%, and on
lacebo 32%, of the subjects failed cardioversion (10). The
nability to be cardioverted may have been related to
onditions that were responsible for the diminished perfor-
ance and QOL in the fibrillation group independently of
he presence of AF.
igure 3. Sinus rhythm (SR) versus atrial fibrillation (AF) comparisons on
aseline to 1 year. †SR group: n  213; AF group: n  145. ‡SR group:
able 4. Correlations (r) Between Maximal Exercise
erformance and Quality of Life (QOL) Measures
QOL Measures
ETT Duration
at 8 weeks
ETT Duration
at 1 yr
SR
Group
AF
Group
SR
Group
AF
Group
F-36 physical functioning 0.28‡ 0.36‡ 0.47‡ 0.10
F-36 physical role limitations 0.15* 0.28‡ 0.30† 0.02
F-36 general health 0.20† 0.07 0.21† 0.03
F-36 vitality 0.13 0.19* 0.20† 0.12
F-36 bodily pain 0.09 0.07 0.25‡ 0.04
F-36 social function 0.16* 0.04 0.19† 0.002
F-36 emotional role
limitations
0.17* 0.14 0.19† 0.05
F-36 mental health 0.07 0.03 0.05 0.01
AS functioning capacity 0.39‡ 0.42‡ 0.49‡ 0.12
p  0.05; †p  0.01; ‡p  0.001.e
AF  atrial fibrillation; ETT  exercise treadmill test; SAS  specific activity
cale; SF-36  Medical Outcomes Study Short Form 36.orrelation between QOL and EP. The exercise data
resented here and obtained from a homogeneous popula-
ion with persistent AF have not only confirmed that
xercise duration increases significantly when AF patients
ave been converted to SR (28,29) but also demonstrated a
tatistically significant association between QOL and EP for
atients in SR versus those in AF. We correlated exercise
uration and raw QOL scores at 8 weeks and at 1 year. It is
oted that EP as an objective measure of physical function
orrelated not only with self-reported physical functioning,
uch as physical functioning, physical role limitation, gen-
ral health, and functioning capability, but also with emo-
ional and social function in patients with SR at 8 weeks and
t 1 year. It bears emphasis that at 1 year the 8 measures that
ere significant in SR were moderately or strongly
orrelated with exercise performance. It is striking that
xercise performance did not correlate with QOL in any
atient groups with AF at 1 year. The fact that the 1-year
R data was an improvement over the degree of correla-
ion between QOL and exercise duration at the 8-week
ollow-up indicates the importance of restoration and
ong-term maintenance of sinus rhythm in patients with
ersistent AF.
linical significance of QOL. The SF-36 is a general
OL instrument that has been found to discriminate
mong various disease states but is less sensitive to
hanges within a particular disease state. Nevertheless,
e found significant improvements in 4 of the 5 physical-
elated subscales at 8 weeks and in 2 of the subscales at 1
ear among patients who maintained SR. In particular,
ignificant improvements in 4 subscales at 8 weeks and in
subscales at 1 year were found in patients who had AF
ymptoms. Research in patients with chronic diseases
ndicates that a 3- to 5-point improvement in SF-36
ubscales is considered to be clinically important (30). An
increase in maximal exercise duration from baseline to 8 weeks and from
219; AF group: n  113.ffect size of at least 0.2 SD units is generally regarded as
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August 15, 2006:721–30 QOL With Sinus Rhythm or AFhe threshold of clinical importance. Our data have
hown that favorable changes in those SF-36 subscales in
R patients compared with those in AF patients were
rom 4.1 to 7.1 points; the effect sizes for maintaining SR
n these subscales ranged from 0.23 to 0.41 standard
eviation units. Thus, using either approach, the data on
OL presented here are both statistically significant and
linically relevant.
tudy limitations. The major limitation of the substudy is
hat the groups compared here (AF, SR) were not con-
tructed by randomization. However, the only fair way to
etermine the differences between SR and AF is to analyze
he data according to rhythm status rather than using the
ntention-to-treat principle. Other unmeasured factors may
ave differed at baseline between those who were in SR at 8
eeks or 1 year and those who were in AF. It is possible that
he inability to cardiovert a proportion, albeit relatively
mall, may have identified a different population, and this
ight have influenced the outcome. However, we con-
ucted analyses which adjusted for known baseline differ-
nces and found the effects on QOL and exercise duration
ere not diminished after statistical adjustment. Moreover,
atients who were able to complete exercise testing at
aseline but not during follow-up were excluded from the
nalyses of changes in duration. Because patients in AF
uring follow-up were more likely not to complete
ollow-up exercise testing, our comparisons between the SR
nd AF group may have underestimated the benefits of SR
n exercise duration. Adequate rate control in AF patients
ight not have been achieved in our study compared with
thers. This may have influenced our results. However, the
ptimal heart rate in AF relating to quality of life measures
as not been defined.
onclusions. The results of this substudy of the SAFE-T
tudy have demonstrated that, in patients with persistent
F, restoration and maintenance of SR is associated with
mprovement in a number of QOL measures. These include
hysical functioning, general health, vitality, and social
unctioning as well as disease-specific QOL measures such
s SCL, SAS, and AFSS. The data have indicated that
atients having symptoms at baseline were more likely to
erive improvement in QOL than those without symptoms.
he improvements in QOL during SR were present at both
hort and long terms. There was a stronger correlation
etween QOL scores and exercise duration on treadmill in
atients with SR than in those with AF. The data under-
core the importance of restoration and maintenance of SR
n patients with AF in the overall management of the
rrhythmia.
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